Key Points
- Insider Nishant Saxena bought 2,600 CRBP shares for approximately $25,038 at $9.63 per share, increasing his direct holdings by 3.45% to 77,900 shares.
- Corbus Pharmaceuticals reported a quarterly loss of $1.81 per share, missing the $1.26 analyst consensus. Analysts expect a full-year loss of approximately $5.22 per share.
- The stock was trading near $9.76, while analysts maintained an overall “Moderate Buy” rating with a consensus price target of $41.12; institutional investors own 64.64% of the company.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) insider Nishant Saxena acquired 2,600 shares of the company's stock in a transaction dated Tuesday, August 11th. The stock was acquired at an average price of $9.63 per share, for a total transaction of $25,038.00. Following the completion of the purchase, the insider directly owned 77,900 shares of the company's stock, valued at $750,177. This trade represents a 3.45% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Corbus Pharmaceuticals Stock Up 2.6%
Shares of NASDAQ:CRBP opened at $9.76 on Thursday. The company has a market cap of $182.22 million, a price-to-earnings ratio of -1.58 and a beta of 2.59. The business has a 50 day moving average price of $8.84 and a 200 day moving average price of $9.07. Corbus Pharmaceuticals Holdings, Inc. has a twelve month low of $7.12 and a twelve month high of $20.56.
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.55). Analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -5.22 EPS for the current year.
Analysts Set New Price Targets
CRBP has been the topic of several research reports. Wall Street Zen downgraded shares of Corbus Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday, August 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research report on Friday, July 17th. Wedbush lowered their price target on Corbus Pharmaceuticals from $38.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 27th. Mizuho lowered their price target on Corbus Pharmaceuticals from $44.00 to $34.00 and set an "outperform" rating on the stock in a research note on Tuesday, June 23rd. Finally, Jefferies Financial Group cut their price target on Corbus Pharmaceuticals from $36.00 to $33.00 and set a "buy" rating for the company in a report on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, Corbus Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $41.12.
View Our Latest Stock Report on Corbus Pharmaceuticals
Institutional Investors Weigh In On Corbus Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of CRBP. Bank of New York Mellon Corp acquired a new position in shares of Corbus Pharmaceuticals in the 2nd quarter valued at $425,000. Seven Fleet Capital Management LP boosted its position in shares of Corbus Pharmaceuticals by 51.0% during the 1st quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company's stock valued at $805,000 after acquiring an additional 28,937 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Corbus Pharmaceuticals by 53,592.3% during the 1st quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company's stock valued at $131,000 after acquiring an additional 13,934 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Corbus Pharmaceuticals by 81.2% during the 1st quarter. Royal Bank of Canada now owns 29,901 shares of the biopharmaceutical company's stock valued at $281,000 after acquiring an additional 13,401 shares in the last quarter. Finally, Exome Asset Management LLC increased its stake in Corbus Pharmaceuticals by 67.8% in the first quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company's stock valued at $2,199,000 after acquiring an additional 94,593 shares during the period. Institutional investors own 64.64% of the company's stock.
Corbus Pharmaceuticals News Summary
Here are the key news stories impacting Corbus Pharmaceuticals this week:
- Positive Sentiment: Director Nishant C. Saxena purchased 2,600 CRBP shares for approximately $25,038 at an average price of $9.63, increasing his direct ownership by 3.45%. Insider buying can signal management confidence in the company’s valuation. SEC insider ownership filing
- Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target, substantially above recent trading levels. The firm continues to model a return to profitability by 2030, although its estimates were lowered.
- Neutral Sentiment: Reported short interest was listed at zero shares, producing a zero-day short-interest ratio. Because the data showed no short position and no meaningful change, it provides little actionable signal for investors.
- Negative Sentiment: HC Wainwright cut EPS forecasts across 2026-2030, including 2026 to a loss of $6.11 per share from $4.99, 2027 to a loss of $6.83 from $5.66, and 2030 profit to $0.15 from $1.29. The revisions point to weaker near- and long-term earnings expectations despite the Buy rating.
- Negative Sentiment: CFO Sean Moran sold 12,000 shares for approximately $120,960, reducing his holdings by 12.41%. The sale may weigh on sentiment, although insider transactions do not necessarily indicate a change in the company’s outlook. CFO stock sale report
- Negative Sentiment: Corbus recently reported a quarterly loss of $1.81 per share, missing the $1.26 consensus estimate, reinforcing concerns about continued cash burn and execution risk for its clinical-stage pipeline.
About Corbus Pharmaceuticals
(
Get Free Report)
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.
Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
